The woman, from Essex, received the six figure sum after she became addicted to the video puzzle game when she was prescribed ...

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The past 50 years have seen remarkable advances in the science of medicine. The pharmacological treatments of disorders such as hypertension, immune disorders, and cancer are fundamentally different ...

Methods: A retrospective drug utilization evaluation was conducted in patients who received levodopa or dopamine agonist for RLS from July 1, 2006, to July 31, 2007. Patients' medical records were ...

The concept of “dopamine dressing,” popularized by fashion psychologist Dr. Dawnn Karen, explores this link between clothing and emotional well-being. Rooted in color psychology and self ...